Comparison of the Biomedica NT-proBNP enzyme immunoassay and the Roche NT-proBNP chemiluminescence immunoassay: Implications for the prediction of symptomatic and asymptomatic structural heart disease

Clinical Chemistry

Volumn 49, Issue 6, 2003, Pages 976-979

  Mueller, Thomas ^a   Gegenhuber, Alfons ^a   Poelz, Werner ^b   Haltmayer, Meinhard ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b JOHANNES KEPLER UNIVERSITY LINZ   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN NATRIURETIC PEPTIDE;

ADULT; AGED; ARTICLE; CHEMOLUMINESCENCE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE MARKER; ENZYME IMMUNOASSAY; FEMALE; HEART DISEASE; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; PREDICTION;

ADULT; AGED; CARDIOMYOPATHIES; CHEMILUMINESCENT MEASUREMENTS; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; NERVE TISSUE PROTEINS; PEPTIDE FRAGMENTS; PROGNOSIS;

EID: 0038021197     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/49.6.976     Document Type: Article

References (12)

1. Hammerer-Lechner A, Puschendorf B, Mair J. Cardiac natriuretic peptides: new laboratory parameters in heart failure patients [Review]. Clin Lab 2001;47:265-7.
2. Mair J. Role of cardiac natriuretic peptide testing in heart failure [Editorial]. Clin Chem 2002;48:977-8.
3. Missbichler A, Hawa G, Woloszczuk W, Schmal N, Hartter E. Enzymimmunoassays für proBNP Fragmente (8-29) und (32-57). J Lab Med 1999;23:241-4.
4. Hammerer-Lechner A, Neubauer E, Muller S, Pachinger O, Puschendorf B, Mair J. Head-to-head comparison of N-terminal pro-brain natriuretic peptide, brain natriuretic peptide and N-terminal pro-atrial natriuretic peptide in diagnosing left ventricular dysfunction. Clin Chim Acta 2001;310:193-7.
5. Stanek B, Frey B, Hulsmann M, Berger R, Sturm B, Strametz-Juranek J, et al. Prognostic evaluation of neurohumoral plasma levels before and during β-blocker therapy in advanced left ventricular dysfunction. J Am Coll Cardiol 2001;38:436-42.
6. Dudek D, Rzeszutko L, Petkow Dimitrow P, Bartus S, Sorysz D, Chyrchel M, et al. Circulating N-terminal brain natriuretic peptide precursor and endothelin levels in patients with syndrome X and left bundle branch block with preserved systolic function. Int J Cardiol 2001;79:25-30.
7. Clerico A, Del Ry S, Giannessi D. Measurement of cardiac natriuretic hormones (atrial natriuretic peptide, brain natriuretic peptide, and related peptide) in clinical practice: the need for a new generation of immunoassay methods [Review]. Clin Chem 2000;46:1529-34.
8. Karl J, Borgya A, Gallusser A, Huber E, Krueger K, Rollinger W, et al. Development of a novel, N-terminal-proBNP (NT-proBNP) assay with a low detection limit. Scand J Clin Lab Invest Suppl 1999;230:177-81.
9. Hunt SA, Baker DW, Chin MH, Cinquegrani MP, Feldman AM, Francis GS, et al. ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: Executive Summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines [Guideline]. Circulation 2001;104:2996-3007.
10. Passing H, Bablok W. A new biometrical procedure for testing the equality of measurements from two different analytical methods. Application of linear regression procedures for method comparison studies in clinical chemistry, Part I. J Clin Chem Clin Biochem 1983;21:709-20.
11. Bland JM, Altman DG. Measuring agreement in method comparison studies [Review]. Stat Methods Med Res 1999;8:135-60.
12. Hanley JA, McNeil BJ. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 1983;148:839-43.